What laboratory evaluation and management should be recommended for perimenopausal patients with suspected androgen excess or menstrual irregularity?

Evaluation and Management of Perimenopausal Patients with Suspected Androgen Excess

In perimenopausal patients with suspected androgen excess or menstrual irregularity, measure early morning total testosterone (days 4-10 of cycle if still cycling) as the initial test, and if elevated or if clinical suspicion remains high despite normal results, proceed with comprehensive hormonal evaluation including DHEAS, 17-hydroxyprogesterone, prolactin, and pelvic ultrasound to exclude PCOS, neoplasms, and other endocrinopathies 1.

Initial Risk Stratification

The perimenopause presents unique diagnostic challenges because normal age-related hormonal fluctuations can mask or mimic androgen excess. Your first task is to determine whether laboratory evaluation is warranted based on clinical features:

Proceed directly to hormonal testing if any of the following are present:

• Moderate to severe hirsutism (Ferriman-Gallwey score >15)
• Menstrual irregularity with accompanying signs: acne, seborrhea, androgenic alopecia, central obesity, or acanthosis nigricans
• Rapid onset or progression of androgenic symptoms
• Any virilization features (clitoromegaly, deepening voice, male-pattern baldness, increased muscularity)
• Palpable abdominal or pelvic mass 1

Even mild hirsutism warrants investigation in perimenopausal women when accompanied by menstrual irregularity, as this combination is usually associated with hyperandrogenemia 1.

Laboratory Evaluation Algorithm

First-Line Testing

Measure early morning (before 10 AM) total testosterone on days 4-10 of the menstrual cycle in women still cycling regularly. This timing is critical because norms are standardized for this window 1.

Critical caveat: Standard immunoassays often fail to accurately measure testosterone in women. If initial testosterone is normal but clinical suspicion remains high or symptoms progress despite therapy, recheck both total and free testosterone in a specialty laboratory using mass spectrometry 1.

Comprehensive Hormonal Panel When Testosterone is Elevated

Once hyperandrogenemia is confirmed, the following tests are essential to identify the source and exclude serious pathology 1:

• Pregnancy test (if amenorrheic)
• DHEAS (early morning): Values >700 μg/dL suggest adrenal androgen-secreting tumor 2
• 17-hydroxyprogesterone (early morning, follicular phase): To exclude non-classic congenital adrenal hyperplasia, particularly in high-risk patients 1, 3
• Prolactin (morning, resting, NOT postictal): To exclude hyperprolactinemia 1, 3
• LH and FSH (average of three samples 20 minutes apart, days 3-6 of cycle): LH/FSH ratio >2 suggests PCOS; FSH >35 IU/L indicates ovarian failure 3
• Mid-luteal progesterone: Values <6 nmol/L indicate anovulation 3

Additional Metabolic Assessment

Given the strong association between hyperandrogenism (particularly PCOS) and metabolic dysfunction, assess for:

• Fasting glucose and insulin (glucose/insulin ratio <4 suggests insulin resistance)
• Lipid panel
• TSH (thyroid dysfunction can cause menstrual irregularity and must be excluded) 1, 4

The metabolic evaluation is critical because 40-45% of PCOS patients have impaired glucose tolerance or type 2 diabetes at initial presentation, and these conditions significantly impact long-term morbidity and mortality 4.

Imaging Studies

Pelvic ultrasound (transvaginal preferred, days 3-9 of cycle) is essential to:

• Detect ovarian neoplasms
• Identify polycystic ovaries (>10 peripheral cysts 2-8mm diameter in one plane, with stromal thickening) 1, 3

When to pursue adrenal imaging: If DHEAS is markedly elevated (>700 μg/dL) or if clinical features suggest Cushing's syndrome, obtain adrenal CT 1, 2.

Red Flags Requiring Urgent Evaluation

Immediately pursue imaging and consider neoplasm if:

• Testosterone >150 ng/dL (5.2 nmol/L)
• Rapid onset and progression of symptoms
• Virilization features present
• Palpable mass on examination 4, 1, 2

These features suggest androgen-secreting tumors (ovarian or adrenal), which carry significant mortality risk if diagnosis is delayed 4, 5.

Differential Diagnosis Considerations Specific to Perimenopause

The perimenopausal transition complicates diagnosis because:

1. PCOS remains the most common cause even in this age group, though symptoms may have been previously unrecognized 6, 5

2. Ovarian hyperthecosis becomes more prevalent and can present with severe hyperandrogenemia mimicking tumors 4, 2

3. Early ovarian failure may coexist with or be mistaken for PCOS-related menstrual irregularity 3

4. Hypothalamic amenorrhea affects approximately 12% of women with temporal lobe epilepsy (if relevant) versus 1.5% of the general population 3

Management Principles

Once etiology is established:

For PCOS or functional hyperandrogenism:

• Hormonal contraceptives are first-line for menstrual irregularities and hirsutism/acne 6
• Metformin for metabolic abnormalities and menstrual irregularities 6
• Address cardiovascular and diabetes risk aggressively given the 40-45% prevalence of glucose intolerance 4

For neoplasms: Surgery is the cornerstone of treatment 5

For non-classic CAH: Glucocorticoid therapy may achieve remission if treated for 1-2 years 4

Critical Pitfall to Avoid

Do not dismiss mild symptoms or treat empirically without establishing diagnosis. Many perimenopausal women receive hormonal contraceptives to "regulate cycles" without proper evaluation, missing opportunities for early intervention that could prevent long-term metabolic complications including diabetes, dyslipidemia, and cardiovascular disease 4. Early diagnosis is critical because hyperandrogenism in women is often a forerunner of metabolic disturbances with major health impacts 4.

The key is recognizing that even subtle menstrual irregularities in perimenopause, when accompanied by any androgenic features, warrant full evaluation rather than attribution to normal menopausal transition 4, 1.